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ABSTRACT:
Introductions & Aims: Heart failure (HF) is a common comorbidity in patients undergoing 
surgical aortic valve replacement (SAVR) and transcatheter aortic valve replacement (TAVR). 
We sought to access the temporal trends and outcomes of TAVR or SAVR in HF patients.
Method: The NIS database from 2011-2014 was queried for patients that underwent TAVR or 
SAVR and were subsequently diagnosed with HF. Temporal trends in the utilization of TAVR or 
SAVR in HF patients were analyzed.
Results: Among 27,982 patients who were diagnosed with HF of whom 17,681 (63.2%) had 
heart failure with reduced ejection fraction (HFrEF) while 10,301 (36.8%) had heart failure 
with preserved ejection fraction (HFpEF), 9,049 (32.3%) underwent TAVR and 16,933 (76.7%) 
underwent SAVR. Patients with HFrEF and HFpEF had higher utilization of TAVR compared to 
SAVR over the course of the study period (p trend < 0.001). TAVR was associated with lower 
mortality [2.8% in 2012 and 1.8% in 2014 (p 0.013)] compared with SAVR. Similarly, multiple 
logistic regression showed a statistically significant lower in-hospital mortality in the TAVR 
group compared to SAVR (aOR 0.634; CI 0.504, 0.798, P < 0.001).
Conclusion: For patients with severe aortic valve stenosis and heart failure who undergo aortic 
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What’s Known:
● Transcatheter aortic valve replacement (TAVR) or surgical aortic valve replacement 
(SAVR) are frequently done for asymptomatic or severe symptomatic aortic stenosis (AS)
● Efficacy of TAVR or SAVR, and its general complications are well reported
What’s New: 
● Research focus of TAVR or SAVR outcomes in subset of patients with heart failure (HF) 
either HF with either preserved ejection fraction (HFpEF) or reduced ejection fraction 
(HFrEF) have been scarcely discussed in literature
● With the rising prevalence of HFpEF and HFrEF in severe AS, the patients can have worse 
complications posing to high post-surgical morbidity, and mortality, hence this study 
done to enlighten this focus.
● The comparison of TAVR with SAVR showed lower mortality in TAVR as compared to 
SAVR in heart failure patients.
INTRODUCTION:
Aortic stenosis (AS) is the most common valvular heart disease in developed countries 1. The 
prevalence of AS ranges from 3 to 23% 2-4. Transcatheter aortic valve replacement (TAVR) is 
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symptomatic aortic stenosis and high surgical or intermediate risk with STS or EuroSCORE II 
score ≥ 4% or those who are frail 5,6. Recent studies showed favorable outcomes of TAVR for 
low risk patients with comparable rates of mortality, stroke and vascular complications 7-10. 
Patients with heart failure (HF), advanced age, hypertension and diabetes who develop aortic 
stenosis often have higher STS risk and EuroSCORE scores compared with patient who do not 
have these comorbidities; at which TAVR is considered more suitable than SAVR due to high 
surgical mortality and morbidity 9.  Limited clinical data suggested no difference in mortality 
and stroke between TAVR and SAVR in patients with left ventricular (LV) dysfunction 11,12. 
Indeed, reports from the Transcatheter Valve Therapy (TVT) registry showed that LV 
dysfunction is present in approximately 25% of TAVR cases13 and reduced LV ejection fraction 
(EF) was associated with higher rates of mortality and recurrent HF in TAVR patients compared 
with patients with preserved LV ejection fraction 14. However, there is limited data available on 
the temporal trends of utilization of TAVR or SAVR and outcomes in patients with severe aortic 
stenosis and heart failure with reduced ejection fraction (HFrEF) or heart failure with preserved 
ejection fraction (HFpEF). Therefore, we sought to evaluate the temporal trends and in-hospital 
outcomes among HFrEF and HFpEF patients undergoing TAVR versus SAVR.
METHODS:
Study population:
The National Inpatient Sample (NIS) is a publicly available and identified database of hospital 
discharges in the United States, containing data from approximately 8 million hospital stays that 
were selected using a complex probability sampling design. It is the weighting scheme 
recommended by the Agency for Healthcare Research and Quality which is intended to 
represent all discharges from nonfederal hospitals15. Each record includes one primary 
diagnosis and up to 24 secondary diagnosis codes between 2009 and 2013, and 29 secondary 
diagnosis codes in 2014. We obtained NIS data from 2011 to 2014 and used the International 
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patients 18-years of age or older, who were diagnosed with chronic systolic and chronic 
diastolic heart failure using the ICD-9 codes 428.22 and 428.32, respectively. Patients with 
combined systolic and diastolic heart failure were excluded due to potential selection bias. ICD-
9 was used to select patients who underwent TAVR (codes 35.05 and 35.06), and SAVR (codes 
35.21 and 35.22), retrospectively. 
Patient and Hospital Characteristics:
Baseline patient-level characteristics included demographics (age, sex, race, primary expected 
payer, median household income for patient’s zip code), urgency of the procedure (elective vs 
non-elective), all of the Elixhauser comorbidities - except congestive heart failure and valvular 
disease -, such as smoking, hyperlipidemia, coronary artery disease (CAD), prior percutaneous 
coronary intervention (PCI) or coronary artery bypass grafting (CABG), history of 
stroke/transient ischemic attack (TIA), atrial fibrillation, and carotid artery disease. Hospital-
level characteristics were census region, bed size, and teaching status. Using the Clinical 
Classification Software codes provided by the Healthcare Cost and Utilization Project and the 
Elixhauser Comorbidity Index comorbidities were appointed via ICD-9 codes, we created a list 
of ICD-9-CM codes and Clinical Classification Software codes to identify comorbidities 
(supplemental table 1).
Outcome measures:
The primary outcome of interest was in-hospital mortality of SAVR or TAVR across heart failure 
including HFrEF and HFpEF. The secondary outcomes include major vascular complications 
(vessel puncture/injury, major bleeding i.e. retroperitoneal hematoma), cardiac complications 
(hemopericardium, cardiac tamponade), respiratory complications (iatrogenic acute 
pneumothorax, postoperative pulmonary edema, respiratory failure, prolonged mechanical 
ventilation >96 hours, tracheostomy), postprocedural stroke and acute kidney injury (AKI). 
Length of stay (LOS) was included in the secondary outcomes. ICD-9-CM diagnosis codes were 
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Statistical analysis:
Continuous variables were expressed as weighted mean values ± standard deviation (normal 
distribution) or median with interquartile range (non-normal distribution), while categorical 
variables were expressed as percentages. Independent t-tests were used for the comparison of 
continuous variables measurements, while chi-square test for categorical variables. Weighted 
values of patient level observations were generated to produce a nationally representative 
estimate of the entire US population of hospitalized patients. Multiple logistic regression 
analyses were used to evaluate the odds of in-hospital mortality and complications for the 
patients that underwent TAVR and SAVR. The regression models were adjusted for 
demographics (age, race and gender), patients’ insurance, socioeconomic status, hospital 
characteristics, procedure urgency (elective vs. non-elective) and all comorbidities listed in 
table 1. Adjusted odds ratios (aORs) and 95% confidence intervals (CIs) were used to report the 
results of regression models. Linear regression models were used to assess the LOS. Log 
transformation of LOS was done to adjust for positively skewed data. 
To further explore the validity of our findings, we stratified patients by heart failure subtype 
defined as heart failure with reduced ejection fraction and heart failure with preserved ejection 
fraction. We also performed propensity score-matching analysis between TAVR and SAVR 
groups. All patients in both groups were matched for baseline characteristics, hospital 
characteristics, patients’ socioeconomic status, insurance and urgency of the procedure in 1:3 
propensity score matching analysis, using the nearest neighbor method. For the trend analysis, 
Cochrane-Armitage test was used to determine the presence of a linear trend between SAVR 
and TAVR utilization over the studied calendar years. P-value of less than 0.05 was considered 
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A total of 27,973 patients were identified with the diagnosis of heart failure from 2011 to 2014. 
Out of 27,973 patients, 18,899 (67.5%) underwent SAVR and 9,074 (32.4%) underwent TAVR. 
Baseline characteristics for both groups are summarized in table 1. Compared to patients who 
underwent SAVR (mean age 70.40 ± 12.1 years), patients who underwent TAVR were older 
(mean age 81.71 ± 7.6 years), more likely to be women and less likely to be African American (p 
<0.001 for all). The prevalence of diabetes, dyslipidemia, hypertension, prior stroke/transient 
ischemic attack (TIA), percutaneous coronary intervention (PCI) or coronary artery bypass 
graft surgery (CABG), renal failure, peripheral vascular disease, and deficiency anemia were 
higher among patients who underwent TAVR. Coagulopathy, fluid and electrolyte disturbances, 
and drug abuse were more prevalent in SAVR patients (p ≤ 0.002 for all). Patients who 
underwent TAVR were less likely to have private insurance, and less likely to have median 
household income in the lowest quartile, compared with patients who underwent SAVR (p < 
0.001). Elective admissions were more frequent in patients who underwent TAVR (p < 0.001).
Using the Cochrane-Armitage method, we found a statistically significant linear uptrend in the 
utilization of TAVR in heart failure patients from 154 (4.0%) to 4,765 (46.7%) cases between 
the years 2011 and 2014; whereas the linear trend for the utilization of SAVR was down 
trending from 3,723 (96.0%) to 5,450 (53.4%) cases between 2011 and 2014 (P-Trend < 0.001, 
for all) (figure 1 and 2). Furthermore, both HFrEF and HFpEF patients had an uptrend in the 
utilization of TAVR and downtrend in the utilization of SAVR during the studied years (P-Trend 
< 0.001 for all). As for mortality, HF patients who underwent either TAVR or SAVR had a 
downtrend in mortality rate between the years 2011 and 2014 (P-Trend < 0.001 for all).
In-Hospital Outcomes
In-hospital mortality was significantly lower in patients who underwent TAVR compared to the 
ones underwent SAVR (1.8% vs 3.0%, p < 0.001). After adjusting for patients’ demographics, 
procedure urgency, comorbidities, insurance and socioeconomic status using multivariate 
regression mode, TAVR patients remained at lower risk of in-hospital mortality (adjusted OR: 
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statistically significant shorter LOS in the TAVR group (median LOS= 5 days; Interquartile range 
[IQR] (3-7)) compared to those with SAVR (median LOS= 8 days; [IQR] (6-12)) (p < 0.001). 
Patients who underwent TAVR had lower incidence of bleeding requiring transfusion (11.6% vs 
22.5%, p < 0.001), cardiac complications (16.3% vs 19.9%, p = 0.010), respiratory complications 
(11.8% vs 22.4%, p < 0.001), and AKI (13.1% vs 21.0%, p < 0.001) but had higher incidence of 
vascular complications (3.5% vs 2.0%, P < 0.001)  and permanent pacemaker implantation 
(10.0% vs 6.2%, P < 0.001) (figure 3). After multivariable adjustment, the odds of bleeding 
requiring transfusion (adjusted OR: 0.47 [95% CI: 0.43 – 0.52]), cardiac complications (adjusted 
OR: 0.89 [95% CI: 0.82 – 0.97]), respiratory complications (adjusted OR: 0.47 [95% CI: 0.43 – 
0.52]), and AKI (adjusted OR: 0.54 [95% CI: 0.49 – 0.59]) remained significantly lower in the 
TAVR group; whereas post-procedural stroke showed no difference between the TAVR and 
SAVR groups (adjusted OR: 0.97 [95% CI: 0.66 – 1.42]). The TAVR group continued to have 
higher vascular complication and permanent pacemaker rates after multivariable adjustment 
(adjusted OR: 1.96 [95% CI: 1.60 – 2.38] and 1.67 [95% CI: 1.48 – 1.88], respectively) (Table 2).
In the subgroup analysis, TAVR patients had lower in-hospital mortality, bleeding requiring 
transfusion, respiratory complications and AKI in both HFrEF and HFpEF patients (P ≤ 0.037 for 
all); whereas vascular complications and permanent pacemaker implantation remained higher 
in the TAVR patients with HFrEF and HFpEF patients (P ≤ 0.004 for all). Furthermore, after 
removing patients diagnosed with infective endocarditis, HF patients undergoing TAVR had 
lower odds of in-hospital mortality (OR 0.58, [95%, CI: 0.47 – 0.72] P < 0.001) and cardiac 
complications while having higher odds of permanent pacemaker implantation and vascular 
complications compared with those who underwent SAVR.
Propensity-score matching and in-hospital outcomes:
Table 3 demonstrates baseline characteristics of the propensity score matched groups. Patients 
who underwent TAVR had lower in-hospital mortality, bleeding requiring transfusion, 









This article is protected by copyright. All rights reserved
rates of post-procedural stroke and cardiac complications between the TAVR and SAVR groups 
(0.8% vs 1.0%), (16.8% vs 19.0%), respectively, (P ≥ 0.139 for both). Vascular complications 
and permanent pacemaker implantation remained higher in the TAVR group compared with the 
SAVR group (3.7% vs 2.0%) and (10.4% vs 6.7%), respectively, (P ≤ 0.008 for both). Histogram 
of standardized differences of covariates between TAVR and SAVR groups before and after 
matching are shown in supplementary figure 1.
DISCUSSION: 
Using a large nationally representative data between 2011 and 2014, we found that heart 
failure patients who underwent TAVR had lower in-hospital mortality, bleeding requiring 
transfusion, cardiac complications and respiratory complications compared with those who 
underwent SAVR regardless of the type of heart failure. Furthermore, TAVR patients had lower 
length of stay compared to those who underwent SAVR. 
Interestingly, despite the higher percentage of different comorbidities in patients underwent 
TAVR compared to SAVR group, such as: renal failure (37% vs 24%), hypertension (81% vs 
74%), dyslipidemia (69% vs 60%), coronary artery disease (70% vs 60%), history of PCI (22% 
vs 9%) and CABG (23% vs 7%), prior strokes (14% vs 9%), and coexisting chronic pulmonary 
disease (34% vs 25%); outcomes such as mortality (1.8% vs. 3.0%) and the length of stay post 
procedure (5 days vs. 8 days), were more favorable for TAVR than for SAVR in patients with HF.  
Patients with heart failure (HF) and advanced age have higher STS and EuroSCORE, TAVR can 
be preferable in these subsets of patients but long-term age-related outcomes of patients 
undergoing TAVR vs. SAVR is not well known. A review by Alsara et al. included 8 studies (5 
observational, 3 clinical trials), comparing TAVR with SAVR in age >80, the author mentioned 
that elderly individuals who underwent TAVI experienced better in-hospital recovery and 
similar short and mid-term mortality compared to those who underwent SAVR. However, they 
required closer monitoring for higher vascular complications that can require a higher length of 
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SAVR patients by ten years (81.7 vs. 70.4) and had a higher prevalence of female sex (48% vs. 
40%) (Table-1). These differences in the risk profile of the two cohorts, particularly that the 
TAVR cohort was more likely to be elderly and female may contribute to the higher vascular 
complications associated with TAVR compared to SAVR (3.5% vs. 2%); as a consequence of the 
age-related deficient vascular elasticity and narrower vasculature in females 17-19.  Such 
observations could also be further supported by the higher incidences of vasculopathies among 
TAVR patients compared to the SAVR group reflected by higher percentages of PCI, CABG, PVD, 
and CAD records. Nevertheless, the absolute risk of vascular complication was only 1.5% higher 
in the TAVR group compared to SAVR.  
Available data suggested TAVR mortality ranges between 1.1 to 4.2% 8,20,21. Contrary to our 
findings, Brennan and colleagues found from a retrospective data analysis obtained from a 
national surgical database linked to Medicare, that TAVR and SAVR resulted in similar mortality 
and stroke rates in patients with intermediate and high-risk 12.  We think such incongruity 
observations from our analysis due to a few factors in Brennan and colleagues’ study.  First, the 
data comparison between SAVR and TAVR was collected in different time-frames as SAVR data 
was obtained from July 2011, to December 2013, while TAVR data from January 2014, to 
September 2015; which may be meaningful as surgical and interventional techniques had 
advanced between 2011 and 2015.  Second, ventricular remodeling and aortic insufficiency 
degree were not reported, which may jeopardize the sample standardization. Third, the 
statistics of stroke outcomes, which is a primary point of interest, had wide confidence intervals 
in each subgroup which challenge the conclusion accuracy.  In our analysis, we identified 
patients with HF and addressed the outcomes accordingly in SAVR and TAVR patients, making 
the variation in sample characteristics less likely to confound the results. Even in studies 
showing a non-inferiority of TAVR approach based on the mortality outcome, TAVR with such a 
conclusion would present a preferred method giving the less invasive intervention, lower length 
of stay, and less overall complications 22,23.
On the other hand, the need for permanent pacemaker (PP) implant due to significant 
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analysis findings.  One of the most common predictors identified by the need for PP post-TAVR 
is the history of right bundle branch block (RBBB) 24,25. Other factors include left ventricular 
end-diastolic dimension and annulus location and calcification, besides the depth of 
implantation technique, oversizing, and balloon-valvuloplasty 26.  The implant of PP after TAVR 
raises concerns of prolonging the hospitalization and intensive care unit stay, however, in our 
analysis the total length of stay remained shorter in TAVR patients than SAVR with a lower 
mortality rate 27.  Aside from medical factors, patients' socioeconomic status appears to play a 
minor role in our analysis outcome.
Limitations:
Our study has several limitations.  This study is a retrospective observational study, which 
poses a possible selection bias and unmeasured confounding factors. Furthermore, the National 
Inpatient Sample is an administrative database which could be subject to inaccurate coding and 
underreporting of comorbid diagnoses. Furthermore, echocardiogram quantitative data 
regarding ejection fraction were not available. In addition, quality of life and long-term outcome 
would aid further in guidance for therapy choice.  Furthermore, the type of anesthesia used for 
the TAVR procedure was not available. This is important as with early experience, TAVR was 
undertaken under general anesthesia, while in recent years, TAVR now undertaken with 
moderate sedation which might contribute to more favorable outcomes associated with TAVR. 
Despite these limitations, we used a large publicly available database to address the limited data 
around outcomes in HF patients after aortic valve replacement with TAVR compared to SAVR. 
Larger scale prospective studies on the older population are needed to validate our findings and 
to perform long-term survival analysis.
Conclusion:
For high surgical risk patients with severe aortic valve stenosis and heart failure, the utilization 
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Figure legends:
Figure 1. Trends of SAVR and TAVR mortality in heart failure patients 
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Table 1. Baseline characteristics for patients undergoing TAVR and SAVR 
Variable TAVR Group SAVR Group P-Value
Age 81.71 ± 7.69 70.40 ± 12.12 <0.001
Sex














Asian or Pacific Islander 0.7 1.2
Native American 0.0 0.3 
Other 1.4 4.7
Elective hospitalization, % 84.2 75.1 <0.001
Primary expected payer, % <0.001
Medicare 91.6 71.1
Medicaid 0.5 4.4
Private Insurance 6.5 20.5
Self-Pay 0.4 1.7
No Charge 0.1 0.2
Other 1.0 2.1
Median Household Income, % <0.001
0 to 25 percentiles 19.6 22.9
26 to 50 percentiles 24.7 25.7
51 to 75 percentile 28.6 27.0
76 to 100 percentile 27.1 24.4




Location/Teaching Status, % <0.001
Rural 1.0 1.6
Urban Nonteaching 10.8 20.0
Urban Teaching 88.2 78.2















Hypertension 81.3 74.4 <0.001
Dyslipidemia 68.9 59.7 <0.001
Atrial fibrillation 45.3 51.2 <0.001
Carotid disease 6.9 5.9 0.002
Smoking 1.9 8.3 <0.001
Coronary artery disease 70.1 59.9 <0.001
Prior PCI 22.0 9.1 <0.001
Prior CABG 22.7 6.6 <0.001
Prior stroke 13.5 8.8 <0.001
Acquired immune deficiency 0.0 0.1 0.028
Alcohol Abuse 0.9 2.9 <0.001




Chronic blood loss anemia 0.9 1.0 0.383
Chronic pulmonary disease 33.9 24.8 <0.001
Coagulopathy 20.9 34.7 <0.001
Depression 7.5 7.9 0.203
DM, uncomplicated 28.9 27.1 0.002
DM, complicated 5.7 6.7 0.001
Drug abuse 0.1 1.2 <0.001
Hypothyroidism 21.0 14.2 <0.001
Liver disease 2.3 2.1 0.440
Lymphoma 1.2 1.0 0.124
Metastatic cancer 0.4 0.1 <0.001
Solid tumors without metastasis 1.6 1.4 0.103
Fluid and Electrolyte disorders 21.2 34.8 <0.001
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Obesity 15.9 24.3 <0.001
Paralysis 1.3 1.6 0.067
Renal failure 37.2 23.6 <0.001
Peripheral vascular disease 29.9 22.3 <0.001
Pulmonary circulation disorders 4.2 0.9 <0.001
Psychosis 1.2 2.4 <0.001
Peptic ulcer disease 0.0 0.0 0.038
Weight loss 3.5 6.3 <0.001
Abbreviations: CABG – coronary artery bypass grafting; PCI – percutaneous coronary 
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Table 2. In-hospital outcome of Heart failure patient undergoing SAVR or TAVR 
Outcome TAVR SAVR
UOR (95% CI) 
TAVR*






Overall (n) 9,074 18,899
HFrEF 6,820 10,861
HFpEF 2,254 8,047
In-Hospital Mortality 1.8% 3.0% 0.59 (0.49-0.70) 0.63 (0.50-0.79) <0.001 <0.001
HFrEF 1.3% 3.1% 0.41 (0.28-0.61) 0.46 (0.27-0.78) <0.001 0.004
HFpEF 2.0% 3.0% 0.65 (0.53-0.80) 0.62 (0.47-0.82) <0.001 0.001
Length of Stay
Median (IQR)
5 (3-7) 8 (6-12) <0.001
HFrEF (days) 5 (3-7) 8 (6-12) <0.001
HFpEF (days) 5 (3-8) 8 (6-13) <0.001
Transfusion 11.6% 22.5% 0.45 (0.42-0.48) 0.47 (0.43-0.52) <0.001 <0.001
HFrEF 11.0% 21.3% 0.45 (0.39-0.52) 0.49 (0.41-0.58) <0.001 <0.001
HFpEF 11.8% 23.4% 0.43 (0.40-0.47) 0.45 (0.40-0.50) <0.001 <0.001
Vascular Complications 3.5% 2.0% 1.78 (1.53-1.07) 1.96 (1.60-2.38) <0.001 <0.001
HFrEF 2.8% 1.9% 1.53 (1.14-2.06) 3.24 (2.09-5.01) 0.004 <0.001
HFpEF 3.7% 2.1% 1.79 (1.49-2.15) 1.61 (1.27-2.04) <0.001 <0.001
Cardiac Complications 16.3% 19.9% 0.78 (0.73-0.84) 0.89 (0.82-0.97) <0.001 0.010
HFrEF 13.3% 18.7% 0.66 (0.58-0.76) 0.83 (0.69-0.98) <0.001 0.021
HFpEF 17.3% 20.8% 0.79 (0.73-0.86) 0.91 (0.82-1.08) <0.001 0.071
Permanent Pacemaker 
Implantation
10.0% 6.2% 1.67 (1.53-1.83) 1.67 (1.48-1.88) 0.021 <0.001
HFrEF 7.3% 5.0% 1.47 (1.22-1.78) 1.43 (1.12-1.83) <0.001 0.004
HFpEF 10.9% 7.1% 1.59 (1.43-1.77) 1.72 (1.49-1.98) <0.001 <0.001
Respiratory Complications 11.8% 22.4% 0.46 (0.43-0.49) 0.47 (0.43-0.52) <0.001 <0.001
HFrEF 11.0% 21.2% 0.46 (0.40-0.53) 0.62 (0.51-0.74) <0.001 0.037
HFpEF 12.1% 23.4% 0.45 (0.41-0.49) 0.42 (0.37-0.47) <0.001 <0.001
Postprocedural Stroke 1.1% 0.8% 1.32 (1.03-1.70) 0.97 (0.66-1.42) 0.030 0.897
HFrEF
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HFpEF 1.1% 1.0% 1.12 (0.83-1.52) 0.69 (0.43-1.12) 0.427 0.138
AKI 13.9% 21.2% 0.60 (0.56-0.64) 0.54 (0.49-0.59) <0.001 <0.001
HFrEF 16.3% 21.4% 0.71 (0.63-0.80) 0.53 (0.47-0.66) <0.001 <0.001
HFpEF 13.1% 21.0% 0.56 (0.52-0.61) 0.52 (0.46-0.58) <0.001 <0.001
TAVR – Transcatheter aortic valve replacement; SAVR – Surgical aortic valve replacement; UOR – Unadjusted odds 
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Table 3. Baseline characteristics of propensity score matched groups
Variable TAVR Group SAVR Group P-Value
Age 80.08 ± 8.12 76.95 ± 8.54 <0.001
Sex





Asian or Pacific Islander 0.8 1.0
Native American 0.0 0.4
Other 4.2 4.8
Elective hospitalization, % 80.4 77.6 0.079
Primary expected payer, % 0.005
Medicare 91.2 87.0
Medicaid 0.6 1.6
Private Insurance 7.3 9.6
Self-Pay 0.5 0.8
No Charge 0.1 0.0
Other 0.4 0.9
Median Household Income, % 0.598
0 to 25 percentile 19.4 21.5
26 to 50 percentile 25.4 24.5
51 to 75 percentile 27.0 26.2
76 to 100 percentile 28.3 27.8
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Rural 1.2 1.1
Urban Nonteaching 13.5 17.4
Urban Teaching 85.2 81.5






Hypertension 80.5 78.2 0.159
Dyslipidemia 67.7 63.9 0.041
Atrial fibrillation 49.6 53.9 0.028
Carotid disease 6.9 6.8 0.933
Smoking 2.4 4.2 0.016
Coronary artery disease 68.3 64.0 0.019
Prior PCI 15.9 13.0 0.029
Prior CABG 14.9 10.4 <0.001
Prior stroke 12.4 10.5 0.117
Alcohol Abuse 1.1 1.7 0.224




Chronic blood loss anemia 0.9 1.3 0.438
Chronic pulmonary disease 30.9 28.0 0.101
Coagulopathy 25.1 31.2 <0.001
Depression 7.4 8.1 0.520
DM, uncomplicated 30.5 29.1 0.457
DM, complicated 5.7 5.7 0.993
Drug abuse 0.1 0.3 0.306
Hypothyroidism 19.5 17.0 0.097
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Lymphoma 0.8 1.1 0.302
Metastatic cancer 0.3 0.2 0.738
Solid tumors without metastasis 1.8 1.5 0.521
Fluid and Electrolyte disorders 24.6 29.0 0.010
Other neurological disorders 6.4 6.3 0.912
Obesity 17.3 20.2 0.057
Paralysis 1.2 1.4 0.741
Renal failure 33.9 28.6 0.003
Peripheral vascular disease 27.5 24.6 0.082
Pulmonary circulation disorders 2.3 1.2 0.029
Psychosis 1.9 1.9 0.949
Weight loss 3.9 5.2 0.113
Abbreviations: CABG – coronary artery bypass grafting; PCI – percutaneous coronary 
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In-hospital mortality 1.8% 3.3% 0.017
Bleeding requiring transfusion 11.4% 22.3% <0.001
Vascular complications 3.7% 2.0% 0.008
Cardiac complications 16.8% 19.0% 0.139
Permanent pacemaker implantation 10.4% 6.7% <0.001
Respiratory complications 11.7% 21.5% <0.001
Post-procedural stroke 0.8% 1.0% 0.519
AKI 14.2% 23.0% <0.001
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